Teva Pharmaceutical Industries Limited (TEVJF)

OTCMKTS · Delayed Price · Currency is USD
14.00
-3.80 (-21.35%)
At close: Jul 22, 2025
-21.35%
Market Cap18.69B
Revenue (ttm)16.63B
Net Income (ttm)-157.00M
Shares Outn/a
EPS (ttm)-0.14
PE Ration/a
Forward PE6.29
Dividendn/a
Ex-Dividend Daten/a
Volume904
Average Volume504
Open14.00
Previous Close17.80
Day's Range14.00 - 14.00
52-Week Range13.73 - 22.91
Beta0.62
RSI43.31
Earnings DateJul 30, 2025

About Accolade

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange OTCMKTS
Ticker Symbol TEVJF
Full Company Profile

Financial Performance

In 2024, TEVJF's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial Statements

News

Teva CEO: Our supply chain puts us in a strong position

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

8 days ago - CNBC Television

Teva CEO: Our supply chain puts us in a strong position

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

8 days ago - CNBC

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

Teva stock is trading below key levels.

8 days ago - Investor's Business Daily

Teva Pharm Q2 profit beats estimates as branded drugs gain

Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophren...

8 days ago - Reuters

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second-quarter 2025 financial results tomorrow, July 30 . According to Benzinga Pro , the company expects to report second-quarter ea...

9 days ago - Benzinga

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Pharmaceutical Industries Ltd. TEVA will release its second-quarter 2025 financial results tomorrow, July 30.

9 days ago - Benzinga

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential

Teva Pharmaceutical Indus (NYSE: TEVA) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement. Analysts estimate that...

9 days ago - Benzinga

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc . (NASDAQ: VTRS) on Friday announced topline data from a Phase 3 study evaluati...

20 days ago - Benzinga

Looking Into Teva Pharmaceutical Indus's Recent Short Interest

Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has risen 11.82% since its last report. The company recently reported that it has 40.00 million shares sold short , which is 3.5% of al...

4 weeks ago - Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Recognized Among World's Most Sustainable Companies | ...

Teva Pharmaceutical Industries Ltd (TEVA) Recognized Among World's Most Sustainable Companies | TEVA stock news

4 weeks ago - GuruFocus

Teva Releases Q2 2025 Aide Memoire

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its ...

6 weeks ago - GlobeNewsWire

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Viatris Inc. (NASDAQ: VTRS) and Opus Genetics, Inc. (NASDAQ: IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) fo...

6 weeks ago - Benzinga

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...

6 weeks ago - Benzinga

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial re...

6 weeks ago - GlobeNewsWire

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevent...

6 weeks ago - GlobeNewsWire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...

7 weeks ago - PRNewsWire